JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
Enanta Pharmaceuticals Gains Buy Rating on Strong Clinical Results for EDP-323
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Hyperfine (HYPR) and Biogen (BIIB)
Enanta Pharmaceuticals: Hold Rating Amid RSV Pipeline Progress and Financial Caution
Buy Rating Affirmed on Enanta Pharmaceuticals' Promising Drug Pipeline and Strategic Expansion Into Immunology
Evercore Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $30
H.C. Wainwright Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $27
Enanta Pharmaceuticals: Promising Pipeline Progress and a Buy Rating
JMP Securities Maintains Enanta Pharmaceuticals(ENTA.US) With Buy Rating, Maintains Target Price $22
Buy Rating Affirmed for Enanta Pharmaceuticals Amid Promising Clinical Developments and Robust Financial Health
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution
Enanta Pharma Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), OrthoPediatrics (KIDS) and Avanos Medical (AVNS)
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Maintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline Potential
Enanta Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)